Coming from an AI assistant? The figures in most GLP-1 roundups did not survive checking. See which did. The corrected list → Or read the casebook
GLP-1 Semaglutide Rx
Comparison matrix
CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27CapturedNexLife$110semaglutide · captured 2026-08-03Trimi$125tirzepatide · captured 2026-07-27Fifty 410$133tirzepatide · captured 2026-07-27NexLife$147tirzepatide · captured 2026-08-03Mochi Health$178semaglutide · captured 2026-08-03Mochi Health$278tirzepatide · captured 2026-08-03LillyDirect$299tirzepatide · captured 2026-07-27
Prices 35 verified of 82 Rubric v1.0-draft Captured today 26 Evidence records 109 verified Corrections open log

Trial review

This figure has a stated end date

The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.

We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.

SELECT: The approved product and Cardiovascular Outcomes, Explained

Does the drug reduce cardiovascular events in people with obesity and established cardiovascular disease, without diabetes?

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published Updated Sources captured Medically reviewed not yet — why

Direct answer

SELECT was a randomised, double-blind, placebo-controlled, event-driven outcomes trial funded by Novo Nordisk. Approximately a 20% relative reduction in the primary composite; event rate fell from roughly 8.0% to roughly 6.5%. That figure belongs to the population, dose and Mean follow-up approximately 40 months shown below, and describes a group average rather than a prediction for any individual.

Answer last reviewed: 2026-08-03Evidence:
SELECT at a glancepublished, peer-reviewed
Data table
DesignRandomised, double-blind, placebo-controlled, event-driven outcomes trial
PopulationAdults 45 and over with overweight or obesity and established cardiovascular disease, without diabetes
Sample size17604
InterventionThis medicine
ComparatorPlacebo
DurationMean follow-up approximately 40 months
Primary endpointComposite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
Main resultApproximately a 20% relative reduction in the primary composite; event rate fell from roughly 8.0% to roughly 6.5%
NCT NCT03574597 · DOI 10.1056/NEJMoa2307563 · PMID 37952131Last source check: 2026-08-03
How to read SELECT without over-reading it
1Who was eligibleAdults 45 and over with overweight or obesity and established cardiovascular disease, wi2What they receivedSemaglutide3What it was compared againstPlacebo4For how longMean follow-up approximately 40 months5What was measured firstComposite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke6What the group average wasApproximately a 20% relative reduction in the primary composite; event rate fell from ro7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleAdults 45 and over with overweight or obesity and established cardiovascular disease, without diabetes
2What they receivedSemaglutide
3What it was compared againstPlacebo
4For how longMean follow-up approximately 40 months
5What was measured firstComposite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
6What the group average wasApproximately a 20% relative reduction in the primary composite; event rate fell from roughly 8.0% to roughly 6.5%
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Reported resultsNew England Journal of Medicine
Semaglutide 2.4 mg6%Placebo8%
Show this figure as a table
Data table
ItemWeight changeEvidence
Semaglutide 2.4 mg6%published, peer-reviewed
Placebo8%published, peer-reviewed
Group means under trial conditions with lifestyle intervention. Not a prediction for any individual reader.
Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Reported
Liraglutide (SCALE)8%Reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mgSURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.

Frequently asked questions

Does this apply to compounded versions?

No. The trial studied an FDA-approved product at studied doses.

Is this drug as effective as tirzepatide?

By mean reduction across separate trials, no. The efficacy ladder above sets out the figures with the trial that produced each one.

Cite this pageCC BY 4.0

GLP-1 Semaglutide Rx. “SELECT: Semaglutide and Cardiovascular Outcomes, Explained.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/research/select/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4